Get the Stockscreener App
1.67
1.83%
0.03
After Hours:
1.69
0.02
+1.20%
Agenus Inc stock is traded at $1.67, with a volume of 423.05K.
It is up +1.83% in the last 24 hours and down -45.95% over the past month.
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).
See More
Previous Close:
$1.64
Open:
$1.64
24h Volume:
423.05K
Relative Volume:
0.98
Market Cap:
$39.99M
Revenue:
$160.43M
Net Income/Loss:
$-227.64M
P/E Ratio:
-0.0243
EPS:
-68.77
Net Cash Flow:
$-170.79M
1W Performance:
-3.47%
1M Performance:
-45.95%
6M Performance:
-66.80%
1Y Performance:
-85.05%
1-Day Range:
$1.57
$1.685
1-Week Range:
$1.55
$1.79
52-Week Range:
$1.55
$19.69
Agenus Inc Stock (AGEN) Company Profile
Name
Agenus Inc
Sector
Industry
Phone
781-674-4410
Address
3 FORBES ROAD, LEXINGTON, MA
Compare AGEN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AGEN
Agenus Inc
|
1.67 | 39.99M | 160.43M | -227.64M | -170.79M | -68.77 |
|
VRTX
Vertex Pharmaceuticals Inc
|
509.04 | 131.41B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
634.14 | 72.26B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
280.96 | 37.54B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ARGX
Argen X Se Adr
|
605.52 | 37.10B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ONC
Beigene Ltd Adr
|
250.47 | 27.23B | 3.81B | -644.79M | -669.77M | -6.24 |
Agenus Inc Stock (AGEN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-19-24 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Jul-18-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Jul-18-24 | Downgrade | William Blair | Outperform → Mkt Perform |
| Jun-06-23 | Initiated | Robert W. Baird | Outperform |
| Feb-28-23 | Resumed | H.C. Wainwright | Buy |
| Sep-28-22 | Initiated | SMBC Nikko | Outperform |
| Dec-16-21 | Initiated | H.C. Wainwright | Buy |
| Nov-19-19 | Resumed | B. Riley FBR | Buy |
| Apr-22-19 | Initiated | B. Riley FBR | Buy |
| Oct-28-16 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Oct-27-16 | Reiterated | Maxim Group | Buy |
| Mar-11-16 | Upgrade | Maxim Group | Hold → Buy |
| Dec-16-15 | Initiated | Jefferies | Buy |
| Oct-27-15 | Downgrade | Maxim Group | Buy → Hold |
| Jul-27-15 | Reiterated | MLV & Co | Buy |
| Jun-11-15 | Initiated | Oppenheimer | Outperform |
| Jan-12-15 | Reiterated | Maxim Group | Buy |
| Jan-09-15 | Reiterated | MLV & Co | Buy |
| Jan-09-15 | Reiterated | Maxim Group | Buy |
| Dec-19-14 | Reiterated | Maxim Group | Buy |
| May-08-14 | Reiterated | Maxim Group | Buy |
| Mar-14-14 | Reiterated | MLV & Co | Buy |
| Oct-08-13 | Reiterated | Maxim Group | Buy |
| Jan-05-12 | Initiated | William Blair | Outperform |
| Dec-01-11 | Initiated | Global Hunter Securities | Buy |
View All
Agenus Inc Stock (AGEN) Latest News
Breakthrough Cancer Treatment Data: Agenus BOT/BAL Shows Promise Across Multiple Cancers - StockTitan
Agenus stock hits 52-week low at $1.64 amid sharp annual decline By Investing.com - Investing.com South Africa
Agenus stock hits 52-week low at $1.64 amid sharp annual decline - Investing.com Australia
Agenus Unveils Colorectal Cancer Survey Findings, Highlighting the Urgent Need for Treatment Innovation - Lelezard
93% of Doctors Say Current Colorectal Cancer Treatments Fall Short, New Study Shows - StockTitan
H.C. Wainwright maintains neutral on Agenus stock post-10-K filing - Investing.com Australia
AGENUS INC SEC 10-K Report - TradingView
Gilead Sciences : Agenus Closes $150 Million Immuno-Oncology Transaction with Gilead - Marketscreener.com
Agenus (AGEN) Reports Q4 Loss, Lags Revenue Estimates - MSN
Equities Analysts Offer Predictions for Agenus Q1 Earnings - Defense World
HC Wainwright Reaffirms Neutral Rating for Agenus (NASDAQ:AGEN) - Defense World
Agenus stock falls after revenue miss - MSN
Agenus (AGEN) Q4 2024 Earnings Call Transcript - AOL
Agenus stock hits 52-week low at $1.91 amid market challenges - Investing.com Australia
Earnings call transcript: Agenus sees stock jump in Q4 2024 By Investing.com - Investing.com Australia
Agenus Inc. Earnings Call: Mixed Sentiments and Strategic Focus - TipRanks
Agenus stock hits 52-week low at $1.91 amid market challenges By Investing.com - Investing.com South Africa
Agenus Inc. (NASDAQ:AGEN) Q4 2024 Earnings Call Transcript - MSN
Agenus’ Strategic Cost Reductions and CRC Focus Lead to Hold Rating - TipRanks
Agenus Inc (AGEN) Q4 2024 Earnings Call Highlights: Strategic Moves Amid Financial Challenges - Yahoo Finance
Agenus Inc (AGEN) Q4 2024 Earnings Call Highlights: Strategic Mo - GuruFocus.com
Agenus Inc. Reports Strategic Cost Reductions and BOT/BAL Progress - TipRanks
Agenus: Q4 Earnings Snapshot - mySA
Agenus stock falls as Q4 revenue drops sharply - Investing.com India
Agenus stock falls as Q4 revenue drops sharply By Investing.com - Investing.com South Africa
Earnings call transcript: Agenus sees stock jump in Q4 2024 - Investing.com India
Agenus Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Agenus: Q4 Earnings Snapshot -March 11, 2025 at 07:44 am EDT - Marketscreener.com
Agenus to lower annual burn to about $50 mln by mid-2025 -March 11, 2025 at 07:40 am EDT - Marketscreener.com
Agenus Reports Q4 and Year-End 2024 Results; Strategic Operational Improvements and Significant Cost Reductions Enhance Sustainability of Promising BOT/BAL Program - Business Wire
Earnings Scheduled For March 11, 2025 - Benzinga
Agenus Slashes Cash Burn by 50% While Advancing Promising Cancer Drug Program - StockTitan
Class Action Filed Against Agenus Inc. (AGEN) Seeking Recovery for InvestorsContact Levi & Korsinsky - ACCESS Newswire
Contrasting Agenus (NASDAQ:AGEN) and Cortexyme (NASDAQ:CRTX) - Defense World
Agenus (AGEN) Projected to Post Earnings on Tuesday - Defense World
Agenus Inc. to Host Earnings Call - ACCESS Newswire
Agenus stock touches 52-week low at $2.48 amid market challenges - Investing.com Australia
Agenus stock touches 52-week low at $2.48 amid market challenges By Investing.com - Investing.com South Africa
Agenus reports promising sarcoma study results - MSN
Agenus Inc. Sued for Securities Law ViolationsContact Levi & Korsinsky Before November 5, 2024 to Discuss Your RightsAGEN - ACCESS Newswire
AGEN INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Agenus Inc. Investors with Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Shareholders that lost money on Agenus Inc.(AGEN) Urged to Join Class ActionContact Levi & Korsinsky to Learn More - ACCESS Newswire
Agenus Inc Stock (AGEN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.98%
0.03%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):